of Robert Langer, Sc.D., of MIT who serves as chair of the committee,
Henry Brem, M.D., of Johns Hopkins University School of Medicine and Gary
Frashier, of Management Associates.
Named key thought leaders in the area of spinal cord injury research to
advise on the CETHRIN development program.
In May 2007, Alseres formed a scientific and clinical advisory panel. The
panel is composed of some of the world's leading experts in the field of
SCI and nerve repair: John F. Ditunno, Jr. M.D., of Jefferson Medical
College; James Fawcett, M.D., of Cambridge University Centre for Brain
Repair; Michael G. Fehlings M.D., Ph.D., of the University of Toronto and
Principal Investigator in the CETHRIN Phase I/IIa trial; Daniel P.
Lammertse, M.D., of Craig Hospital; John Steeves, Ph.D., of the University
of British Columbia (UBC) and Vancouver Coastal Health (VCH); and Mark
Tuszynski, M.D., Ph.D., of the University of California at San Diego. They
joined the Company's current scientific advisors: Larry Benowitz, Ph.D.,
Children's Hospital Boston; Zhigang He, Ph.D., Children's Hospital Boston;
and Joseph Bianchine, M.D., former advisor to Schwarz Pharma.
Financial Highlights for 2007
-- Cash, cash equivalents and marketable securities at December 31, 2007
totaled $4.2 million as compared to $1.5 million at December 31, 2006.
Convertible notes payable at December 31, 2007 totaled $23.3 million as
compared to $8 million in notes payable at December 31, 2006.
-- Net loss attributable to common stockholders for 2007 was $19.5
million, or $1.04 per share, as compared to a net loss attributable to
common stockholders of $26.4 million, or $1.59 per share, for 2006.
-- Research and development (R&D) expenses totaled $10.5 million during
2007 as compared to $18.5 mill
|SOURCE Alseres Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved